Keyphrases
Drug Discovery
100%
Trypanosoma Brucei
91%
Protein Kinase
85%
Antitrypanosomal Activity
57%
Soft Drugs
57%
Sphingosine-1-phosphate Receptor (S1PR)
57%
Multiple Stages
57%
Antimalarial Drugs
57%
Protein Synthesis
57%
Human African Trypanosomiasis
45%
Molecular Targets
40%
Phenotypic Screening
40%
Pharmacokinetic Properties
39%
Kinase Inhibitor Design
38%
Diaminothiazoles
38%
Malaria
37%
New Drugs
32%
Ponesimod
32%
Esters
32%
Off-target Effects
28%
CRK3
28%
Cdc2
28%
Visceral Leishmaniasis
28%
U50,488
28%
Pyrazolo
28%
Opioid Agonist
28%
Preclinical Development
28%
GSK-3 Inhibitors
28%
2-arylquinazolines
28%
Lead Molecules
28%
T. Brucei
28%
Plasmodium Falciparum
28%
Interleukin-10
28%
Differential Control
28%
High-affinity Interaction
28%
S6 Kinase 1 (S6K1)
28%
IL-10 Production
28%
Macrophage Cells
28%
Replication Licensing
28%
Imidazo
28%
Leishmania
28%
EEF2
28%
S1PR1
28%
Protein Kinase Inhibitors
28%
Small Molecule Inhibitors
28%
Amines
28%
Toll-like
28%
Origin Recognition Complex
28%
Pyridine Scaffold
28%
Dundee
28%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
95%
Protein Kinases
95%
Trypanosoma Brucei
91%
Hexachlorophene
57%
Antimalarial Agent
57%
Sphingosine 1 Phosphate Receptor
57%
Ponesimod
57%
African Trypanosomiasis
57%
Diseases
53%
Molecular Target
36%
Phosphotransferase
36%
Pharmacokinetics
30%
Target Activity
28%
Visceral Leishmaniasis
28%
Plasmodium falciparum
28%
6 Fluoro 2 [4 (Morpholinomethyl)phenyl] 4 [2 (1 Pyrrolidinyl)ethylaminomethyl]quinoline
28%
Topical Agent
28%
Interleukin 10
28%
S6 Kinase
28%
Toll Like Receptor 4
28%
3,4 Dichloro N Methyl N [2 (1 Pyrrolidinyl)cyclohexyl]benzeneacetamide
28%
Opiate Agonist
28%
Leishmania
28%
Drug Concentration
28%
Dermatitis
28%
Phenol
28%
Protein Kinase Inhibitor
28%
Plasmodium
24%
Structure Activity Relationship
24%
Antiproliferative Activity
19%
Phenazone
17%
Esterase
14%
Aryldialkylphosphatase
14%
Clinical Trial
14%
Psoriasis
14%
Side Effect
14%
Therapeutic Window
14%
Lymphocytopenia
14%
Cytostatic
11%
Cycline
9%
Cyclin Dependent Kinase
9%
Leishmaniasis
9%
Messenger RNA
9%
Antimalarial Activity
9%
EC50
9%
Elongation Factor 2
9%
Drug Resistance
9%
Life Cycle Stage
9%
Guanosine Triphosphate
9%
Stress Activated Protein Kinase
8%